The Lithuanian competition authority Konkurencijos taryba has found that the Lithuanian Pharmacy Association (LPA) and 8 pharmaceutical companies agreed on the margins of reimbursable medicines. The infringement of the Law on Competition and the Treaty on the Functioning of the European Union resulted in more than EUR 72 million in fines.
On December 5, 2016 the Competition Council confirmed the final conclusions of the market study on reimbursable pharmaceuticals (hereinafter – Study) that revealed competition problems in the market, to which possible solutions were proposed.
The Competition Council (hereinafter – Council) found that UAB Nemuno vaistinė (hereinafter – Company) made false claims about 30 per cent cheaper products sold in the pharmacies of Camelia (hereinafter – Camelia ), and thus breached Article 5 of the Law on Advertising.
The Competition Council (hereinafter – KT) has submitted its preliminary market study report on reimbursable pharmaceuticals for public consultation. KT experts aimed at finding out if current legal regulation does not create obstacles for pharmaceuticals to enter the market of reimbursable pharmaceuticals and stay in it, and whether competition...
The Lithuanian competition authority conducted a market study on the parallel import of pharmaceuticals. The aim of the study was to assess the situation in the Lithuanian pharmaceutical market and identify the main circumstances determining a low share of the trade of parallel imported pharmaceuticals in Lithuania, as well as to provide proposals on how effective competition could be ensured in the market.